CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer

European Journal of Cancer

Volumn 35, Issue 9, 1999, Pages 1343-1347

  Andre T ^a   Louvet, C ^b   Maindrault Goebel, F ^b   Couteau, C ^a   Mabro, M ^b   Lotz, J P ^a   Gilles Amar, V ^b   Krulik, M ^b   Carola, E ^c   Izrael, V ^a   De Gramont, A ^b  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Hopital de Senlis   (France)

Author keywords

5 Fluorouracil; Irinotecan (CPT 11); Leucovorin; Metastatic colorectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0033198035     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00150-1     Document Type: Article

References (26)

1. Rougier P., Bugat R., Douillard J.Y.et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil based chemotherapy. J Clin Oncol. 15:1997;251-260.
2. Pitot H.C., Wender D.B., O'Connell M.J.et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 15:1997;2910-2919.
3. Cunningham D., Pyrhönen S., James R.D.et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
4. Rougier P., Van Cutsem E., Bajetta E.et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 10:1992;896-903.
6. de Gramont A., Bosset J.F., Milan C.et al. Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French intergroup study. J Clin Oncol. 15:1997;808-815.
7. Tournigand C., de Gramont A., Louvet C.et al. A simplified bimonthly regimen with leucovorin (LV) and 5-fluorouracil (5FU) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 17:1998;274a.
8. de Gramont A., Louvet C., André T.et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-hour continuous infusion in advanced colorectal cancer. Eur J Cancer. 34:1998;619-626.
9. Mullany S., Svingen P.A., Kaufmann S.H.et al. Effect of adding the topoisomerase I poison 7-ethyl 10-hydroxycamptothecin (SN 38) to 5-fluorouracil and folinic acid in HCT8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharm. 42:1998;391-399.
10. Benhammouda A., Bastian G., Rixe O.et al. A phase I and pharmacokinetic study of CPT-11 and 5FU combination. Proc Am Soc Clin Oncol. 16:1997;202a.
11. Khayat D., Gil-Delgado M., Antoine E.C.et al. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Oncology. 12(Suppl. 6):1998;64-67.
12. Ducreux M., Rougier P., Ychou M.et al. Phase I/II study of escalating doses of CPT-11 in combination with LV5FU2 every 2 weeks in the treatment of colorectal cancer after 5FU failure. Proc Am Soc Clin Oncol. 16:1997;234a.
13. André T., Bensmaine M.A., Louvet C.et al. Addition of oxaliplatin (Eloxatine) to the same leucovorin (LV) and 5-fluorouracil (5FU) bimonthly regimens after progression in patients with metastatic colorectal cancer (MCRC). Proceedings of the Annual Meeting ECCO 9. Eur J Cancer. 33(Suppl. 8):1997;S738.
14. Maindrault-Goebel F., de Gramont A., Louvet C.et al. Bimonthly oxaliplatin with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (FOLFOX6). Proc Am Soc Clin Oncol. 17:1998;273a.
15. de Gramont A., Figer A., Seymour M.et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol. 17:1998;257a.
16. Abigerges D., Armand J.P., Chabot C.G.et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 86:1994;446-449.
17. WHO Handbook for Reporting Results of Cancer Treatment. 1979;WHO, Geneva.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
19. MacDonald J., Haller D., Mayer R. Grading of toxicity. MacDonald J., Haller D., Mayer R. Manual of Oncologic Therapeutics. 1995;519-523 Lippincott, Philadelphia.
20. Parnes H.L., Tait N., Conley B.et al. A phase I study of CPT-11, weekly bolus 5FU and leucovorin in patients with metastatic cancer. Oncol Rep. 2:1995;1131-1134.
21. Saltz L.B., Kanowitz J., Kemeny N.E.et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol. 14:1996;2959-2967.
22. Goldberg R.M., Erlichman C. Irinotecan plus 5FU and leucovorin in advanced colorectal cancer: North American trials. Oncology. 12(Suppl. 6):1998;59-63.
23. Paz-Ares L., Sastre J., Diaz-Rubio B.et al. Phase I dose-finding study of irinotecan (CPT-11) over a short IV infusion combined with fixed dose of 5-fluorouracil (5FU) protracted continuous IV infusion in patients with advanced solid tumor. Proc Am Soc Clin Oncol. 16:1997;247.
24. Shimada Y., Sasaki Y., Sugano K.et al. Phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol. 12:1993;196.
25. Matsuoka H., Yano K., Takiguchi S.et al. Advantage of combined treatment of CPT-11 and 5-fluorouracil. Anticancer Res. 15:1995;1447-1452.
26. 2 given every other week in previously treated colorectal cancer patients. Proc Am Soc Clin Oncol. 17:1998;284a.